Molecule intelOpportunity: ModerateEssential

Phenobarbital

16 brands · 15 companies · product forms

ATC: N03AA02 1 DRAP alert

Opportunity snapshot

Launch attractiveness
47
Market saturation
38
Price room
100
Regulatory risk
50
16
brands
15
companies
Rs 100.5
median price
10
price points
107.18x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 13%

Price room

Across observed sources and strengths
CheapestRs 18.28
MedianRs 100.5
Most expensiveRs 1,959.2
Spread107.18×
Sources: DRAP-official

max/min price ratio 107.18x across 10 trusted points (Rs 18.28-1959.2). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 1 live product for Phenobarbital — each links to its own medicine page.

Regulatory alerts

Safety exposurelatest 2023-06-07
Rapid Alert; Drug Product: Falsified Phenobar 30mg Tablets identified in the Market

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(62) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

15 canonical companies and 16 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 107.18x across 10 trusted points (Rs 18.28-1959.2). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2023-06-07 incl. recall/safety.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.